Objectives: Attention deficit hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders of childhood. Although enuresis is a very common disorder in child diagnosed with ADHD, it may also develop because of methylphenidate. Methods: Authors report here on a child case of ADHD that developed a probable enuresis related to methylphenidate. Results and Conclusions: Clinicians should be aware that methylphenidate used in ADHD causes dose-dependent enuresis.
1 September 2016 in Klinik Psikofarmakoloji Bülteni / Bulletin of Clinical Psychopharmacology
Attention-Deficit/Hyperactivity Disorder (ADHD) is the most common neurodevelopmental disorder in children that shows comorbidity with several psychopathology included stuttering. The prefrontal cortex is the area of brain that sends and receives projections from virtually all cortical sensory systems, motor systems, and many subcortical structures. It has been shown that psychostimulant medication increases activation of the inferior prefrontal cortex and the basal ganglia. Both functional neuroimaging and neuropsychological studies show that psychostimulant medication improves executive functions. Verbal fluency is also considered as one of the executive functions. In this article, we report osmotic-controlled release oral delivery system (OROS) methylphenidate treatment effectiveness of stuttering that combined with ADHD.
Aim: Autism spectrum disorder is a neurodevelopmental disorder. The S100 calcium binding protein B (S100B) is among the markers of astrocyte activation as well as brain damage. Herein, it was aimed to evaluate S100B levels to determine whether there is a relation with the severity of autism spectrum disorder and establish possible causes of different results among the studies in the literature from a psychiatric and biochemical perspective. Material and Methods: Twenty-five male children with autism spectrum disorder were included as the study group along with twenty-seven male children as the control group. The childhood autism rating scale and the autism behavior checklist were applied. Serum S100B protein levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: The mean serum S100B level was 1008.61±171.34 pg/mL in the study group and 1060.14±182.83 pg/mL in the control group, and no statistically significant difference was found between the groups (p=0.300). Based on the childhood autism rating scale scores, 60% (n=15) of the children with autism spectrum disorder had severe autism, whereas 40% (n=10) had mild-to-moderate autism. There was no significant difference in terms of the serum S100B levels between the groups of autism spectrum disorder severity (p=0.935) or according to the autistic regression status (p=0.667). Conclusion: For S100B to be accepted as a reliable biomarker for autism spectrum disorder, more studies considering some factors with larger samples should be performed. Moreover, to understand the effect of biochemical methodology on the results, further studies are suggested on this subject.